Shares of Quantinuum (QNT) slid 8.1% to $55.50 on their second day of trading, erasing the first-day pop that had briefly valued the quantum computing company at $17.6 billion. Traders who bought the opening-day surge at $68 are now sitting on a 18.4% loss in barely 24 hours, and the stock has cracked below its own $60 IPO price — a warning sign for what was supposed to be the sector's landmark listing.
The First-Day Pop Was Borrowed Excitement, Not Lasting Conviction. Shares opened at $68, hit a session high of $71.35, then faded to close at roughly the IPO price after Quantinuum raised $1.68 billion at $60 a share — well above its earlier target range of $53 to $55. The pattern is textbook: hype-driven buying gives way to profit-taking, and when the broader Nasdaq drops ~1.8% on the same day, momentum names get punished first. At $55.50, QNT now trades below the price at which the company sold shares to investors, meaning IPO allocators are already underwater.
The Revenue Picture Is Razor-Thin For a $14 Billion Company. Quantinuum reported a $192.6 million net loss against just $30.9 million in revenue for 2025 , and the $60 IPO price valued the company at over 450 times its annual revenue. Even more alarming: revenue fell 73% to $5.24 million in Q1 2026 from $19.1 million a year earlier, while the quarterly net loss ballooned to $136.5 million. Investors are essentially paying for technology that may not reach commercial scale until at least 2029.
Bookings — a Measure of Signed Customer Deals — Are Drying Up. Quantinuum reported $79.3 million in 2025 bookings, but only $1.3 million in Q1 2026. That collapse undercuts the narrative that enterprise demand is accelerating. Without a visible pipeline, the stock rests almost entirely on faith in the quantum computing roadmap.
Honeywell's Grip Limits What New Shareholders Can Influence. Honeywell retains approximately 48.1% of combined voting power, giving the industrial conglomerate a significant voice in strategy while Quantinuum operates as an independent public company.
That limits outside shareholder influence, because public holders are buying into a controlled company whose direction is shaped by its largest backer.
The bottom line: a government endorsement — $100 million from the Commerce Department via the CHIPS Act — and Honeywell's backing are real assets, but they cannot substitute for revenue growth that has yet to materialize. At $55.50, the market is repricing the gap between quantum promise and quantum profit.